Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Beta 2 agonists and asthma.

× No keyword cloud information.

13 in total

1. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol.

Authors: C P van Schayck; S J Graafsma; M B Visch; E Dompeling; C van Weel; C L van Herwaarden
Journal: J Allergy Clin Immunol Date: 1990-11 Impact factor: 10.793

2. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline.

Authors: A S Vathenen; A J Knox; B G Higgins; J R Britton; A E Tattersfield
Journal: Lancet Date: 1988-03-12 Impact factor: 79.321

3. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline.

Authors: J Kraan; G H Koëter; T W vd Mark; H J Sluiter; K de Vries
Journal: J Allergy Clin Immunol Date: 1985-10 Impact factor: 10.793

4. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study.

Authors: J Crane; N Pearce; A Flatt; C Burgess; R Jackson; T Kwong; M Ball; R Beasley
Journal: Lancet Date: 1989-04-29 Impact factor: 79.321

5. Histamine release in vitro: inhibition by catecholamines and methylxanthines.

Authors: L M Lichtenstein; S Margolis
Journal: Science Date: 1968-08-30 Impact factor: 47.728

6. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma.

Authors: K F Kerrebijn; E E van Essen-Zandvliet; H J Neijens
Journal: J Allergy Clin Immunol Date: 1987-04 Impact factor: 10.793

10. Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol.

Authors: M K Church; J Hiroi
Journal: Br J Pharmacol Date: 1987-02 Impact factor: 8.739

8 in total

1. A drug use review study in patients with obstructive lung disease. Assessment of the quality of drug therapy.

Authors: G Van den Brink; C W Bollen; O E Van de Wall; L J Hoeve; A J Porsius
Journal: Pharm Weekbl Sci Date: 1992-10-16

2. The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy.

Authors: M J Sculpher; M J Buxton
Journal: Pharmacoeconomics Date: 1993-11 Impact factor: 4.981

Review 6. Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.

Authors: D Faulds; L M Hollingshead; K L Goa
Journal: Drugs Date: 1991-07 Impact factor: 9.546

Review 7. Future developments in the pharmacotherapy of lung disease.

Authors: A Van der Kuy
Journal: Pharm Weekbl Sci Date: 1992-08-21

Review 8. The epidemiology and therapy of airflow limitation in the elderly.

Authors: L Dow
Journal: Drugs Aging Date: 1992 Nov-Dec Impact factor: 3.923

8 in total

Beta 2 agonists and asthma.

1. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol.

2. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline.

3. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline.

4. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study.

5. Histamine release in vitro: inhibition by catecholamines and methylxanthines.

6. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma.

7. Regular inhaled beta-agonist treatment in bronchial asthma.

8. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.

9. Protection against allergen-induced asthma by salmeterol.

10. Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol.

1. A drug use review study in patients with obstructive lung disease. Assessment of the quality of drug therapy.

2. The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy.

3. Beta 2 agonists and asthma.

4. Strategy for asthma.

Review 5. Long- versus short-acting beta 2-agonists. Implications for drug therapy.

Review 6. Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.

Review 7. Future developments in the pharmacotherapy of lung disease.

Review 8. The epidemiology and therapy of airflow limitation in the elderly.